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Abstract 
Purpose: To report the clinical course and multimodal imaging features of acute zonal occult outer retinopathy 
(AZOOR) complicated by choroidal neovascularization (CNV) treated with anti‑vascular endothelial growth factor 
(VEGF) treatment or photodynamic therapy (PDT).
Methods: Observational case series. Retrospective analysis of patients presenting to different institutions with 
evidence of AZOOR and neovascular lesions. Diagnosis of AZOOR was made on the basis of clinical presentation and 
multimodal imaging. All patients underwent a comprehensive ophthalmic evaluation and multimodal retinal imag‑
ing, including color fundus photos, fundus autofluorescence, fundus fluorescein angiography and spectral‑domain 
optical coherence tomography.
Results: Four patients (three males, mean age 53.5 years) were included in the study. Mean follow‑up was 5.1 years. 
Presentation of AZOOR was unilateral in two patients and bilateral in the remainder two patients. One of the patients 
presenting with unilateral AZOOR developed zonal lesions in the fellow eye during follow‑up. All patients presented 
with unilateral type 2 (subretinal) CNV. Three patients underwent intravitreal anti‑VEGF injections and one patient 
underwent a single PDT. Multimodal retinal imaging showed zonal or multizonal progression during treatment. After 
treatment, visual acuity and CNV stabilization was observed in all patients.
Conclusions: The presence of CNV expands the clinical spectrum of AZOOR. CNV complicating AZOOR may be 
effectively treated with intravitreal injections of anti‑VEGF, despite progression of the zonal lesions. Further studies are 
required to define the role of treatment in the progression of the zonal lesions.
Keywords: Acute zonal occult outer retinopathy, Choroidal neovascularization, Anti‑vascular endothelial growth 
factor treatment, Multimodal retinal imaging
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Background
As originally defined in 1992 by Gass in his Donder’s Lec-
ture [1], acute zonal occult outer retinopathy (AZOOR) 
is a rare, condition of unknown etiology, characterized 
by an acute loss of one or more zones of outer retinal 
function. Since the original report by Gass [1], the term 
AZOOR became a general diagnostic term for chorioreti-
nal diseases with visual loss of uncertain origin. Indeed, 
the definition and classification of AZOOR resulted 
in a heterogenic spectrum of disorders, the so-called 
“AZOOR complex”.
A common feature of the disease is the acute zonal 
lesion, or lesions, delineated by a grayish ring on fun-
duscopy or a demarcation line of hyperautofluores-
cence seen on fundus autofluorescence imaging, which 
has been referred to as acute annular outer retinopathy 
(AAOR) [2]. A more strict definition of AZOOR based 
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on multimodal retinal imaging findings, including a 
demarcating line of progression between the involved 
and uninvolved retina and a trizonal pattern of chorioret-
inal degeneration, has been recently proposed [3, 4].
The development of subretinal choroidal neovascu-
larization (CNV) in AZOOR is an extremely rare event 
[4–6]. Levison et al. [6] recently reported a case of CNV 
in AZOOR but long-term follow-up was not included. 
The purpose of this study is to report in details the clini-
cal course and the multimodal retinal imaging of patients 
presenting with CNV and AZOOR.
Methods
This is an observational case series of patients included 
from the practices of different retina specialists. Clinical 
records and multimodal retinal imaging of patients pre-
senting with AZOOR and neovascular lesions from three 
tertiary referring centers located in Italy (San Raffaele 
Scientific Institute, Vita-Salute University, Milan), France 
(Ophthalmic Center for Imaging and Laser, Paris, France) 
and United States of America (Vitreous Retina Macula 
Consultants of New York, New York) were collected and 
analysed. All patients underwent a comprehensive oph-
thalmic evaluation, including best-corrected visual acuity 
(BCVA), and multimodal retinal imaging, including color 
fundus photography, fundus autofluorescence (FAF), fun-
dus fluorescein angiography (FA) and spectral-domain 
optical coherence tomography (SD-OCT). Indocyanine 
green angiography (ICGA) was available for 3 patients 
(cases 2, 3 and 4).
Wide-field imaging using a system imaging 200° of the 
retina (200Tx; Optos plc) was available for one patient 
(case 3). For the other patients FAF, FA and ICGA were 
obtained using a fundus camera (TRC 501; Topcon Med-
ical Systems) or scanning laser ophthalmoscopy on the 
Heidelberg system (Heidelberg Engineering, Heidelberg).
Diagnosis of AZOOR was made on the basis of clini-
cal presentation and multimodal retinal imaging features 
including: (1) a demarcating line of progression at the 
level of the outer retina; (2) a trizonal pattern of sequen-
tial involvement of the outer retina, retinal pigment epi-
thelium (RPE) and choroid; (3) zonal progression [4].
Extensive laboratory testing was performed in all 
patients to rule out chorioretinal conditions mimick-
ing AZOOR. Humphrey visual field test was performed 
in two patients (cases 1 and 2) and Goldmann dynamic 
perimetry in one patient (case 4).
Demographic and relevant clinical findings available 
at baseline and at all follow-up examination visits were 
reviewed by the authors and retrospectively analyzed. 
Early data from one of the included cases (case 4) have 
been reported by Cohen and Jampol [5].
The study was conducted in agreement with the Decla-
ration of Helsinki for research involving human subjects. 
Informed consent for publication of their clinical details 
and/or clinical images was obtained from the patients.
Results
Four patients (3 males) were included in this study. Two 
patients attended the Vitreous Retina Macula Consult-
ants of New York (cases 1 and 3); one patient attended 
the San Raffaele Scientific Institute in Milan (case 2); one 
patient attended the Ophthalmic Center for Imaging and 
Laser in Paris (case 4).
Demographic characteristics, main presenting symp-
toms and medical history of patients are shown in 
Table  1. The main presenting clinical characteristics of 
patients are shown in Table  2. The characteristics of a 
published case of AZOOR complicated by CNV [6] is 
reported in Tables 1 and 2.
In our series, mean age of the patients at the time of 
presentation was 53.5  year-old, ranging from 33 to 
69  year-old. Central scotoma and photopsia were the 
most common presenting symptoms. AZOOR was uni-
lateral in two patients (cases 1 and 4) and bilateral in the 
remainder two patients (cases 1 and 4). Mean follow-up 
was 5.1  years. One of the patients presenting with uni-
lateral AZOOR developed zonal lesions in the fellow eye 
5 years after presentation (case 4).
Table 1 Demographic characteristics, main presenting symptoms and  medical history of  acute zonal occult outer 
retinopathy complicated by chorodal neovascularization in our series and in the Levison et al.a report
M male, F female
a See Ref. [6]
Patient Gender Age Presenting symptoms Medical history
1 M 65 Central scotoma Systemic hypertension; aortic 
valve replacement
2 M 69 Blurred vision, scotoma, photopsia Systemic hypertension
3 F 33 Central scotoma and distortion Hashimoto’s thyroiditis; ashtma
4 M 47 Blurred vision and photopsia Unremarkable
Levison et al.a F 74 Blurred vision, scotoma, photopsia Not reported
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All patients presented with unilateral type 2 (subreti-
nal) CNV which was treated with intravitreal anti-VEGF 
injections in 3 patients (bevacizumab in two patients; 
ranibizumab and aflibercept in one patient) and Verte-
porfin photodynamic therapy (PDT) in one patient (case 
4). After treatment, visual acuity and CNV stabiliza-
tion was observed in all patients. Multimodal retinal 
imaging showed progression of the zonal lesions during 
treatment.
Case 1
A 65-year-old white male presented 10 days after the 
onset of a central scotoma in the left eye (LE). BCVA at 
presentation was 20/20 in the right eye (RE) and 20/32 in 
the LE. Fundus examination of the LE revealed an area of 
RPE atrophy in the inferonasal macula with foveal spar-
ing (Fig. 1). FAF in the left eye revealed a trizonal pattern 
and a demarcating hyper-FAF line between the involved 
and uninvolved retina (Fig.  2); these findings were con-
sistent with AZOOR [4].
Ten days later, he returned complaining of distortion. 
Fundus examination revealed zonal lesion expansion, 
which was confirmed by FAF. The OCT revealed mild 
subretinal fluid (SRF) which explained his metamor-
phopsia. The patient returned a week later. At this time, 
visual acuity had reduced to 20/60, and two perilesional 
haemorrhages were observed along with a hypo-FAF 
zonal lesion expansion which included the fovea (Fig. 2). 
The OCT showed a significant increase of subretinal 
fluid. These findings were consistent with a type 2 (sub-
retinal) CNV which was confirmed by  fluorescein angi-
ography. Consequently he received 3 monthly intravitreal 
bevacizumab injections. One month after the first injec-
tion, FAF revealed zonal progression (Fig.  2) and OCT 
revealed a worsening of SRF (Fig.  3). One month after 
the third injection, BCVA in the LE was 20/70 and the 
patient reported stabilization of his central scotoma. At 
month 5, BCVA was 20/60; OCT scan showed resolu-
tion of SRF, while FAF revealed minimal advancement of 
zonal lesion size. During follow-up the zonal lesions sta-
bilized; the patient received 11 intravitreal bevacizumab 
injections on a treat and extend regimen for 4 years and 
maintained a BCVA of 20/60 in the LE.
Case 2
A 69-year-old white male was referred for sudden onset 
scotoma with blurriness and photopsia in the LE. BCVA 
was 20/20 in the RE, and 20/40 in the LE. Fundus exami-
nation revealed bilateral peripapillary atrophy and reti-
nal swelling at the macula of the LE (Fig. 4). OCT scan 
and FA revealed a juxtafoveal type 2 CNV in the LE. One 
intravitreal bevacizumab injection was administered in 
the LE. Four 4 weeks after the injection, BCVA was sta-
ble; in the RE the peripapillary lesion extended and new 
zonal lesions were visible temporal to the fovea (Fig. 5); in 
the LE the peripapillary and the macular defect extended 
and merged appearing as a single, large zonal defect 
involving the fovea. FAF in both eyes revealed a trizonal 
pattern and a demarcating hyper-FAF line between the 
involved and uninvolved retina (Fig.  5); these findings 
were consistent with AZOOR [4].
FA showed persistence of leakage from the CNV and 
two additional intravitreal bevacizumab injections were 
administered. One month after the third injection, 
further progression of the zonal lesions was observed 
in both eyes (Fig.  5). SD-OCT scan showed complete 
resolution of the subretinal fluid with persistent well-
defined subretinal hyperreflective material (Fig.  6). 
Since then, the patient has maintained a BCVA of 20/50 
in the LE (and 20/25 in the RE) with no evidence of 
progression of the zonal lesions and CNV stabilization 
during 2 years of follow-up.
Case 3
A 33  year-old white female presented with central 
scotoma and distortion in the RE for 2  months. She 
was 3  months post-partum and nursing at the time of 
Table 2 Clinical characteristics of  acute zonal occult outer retinopathy complicated by  chorodal neovascularization 
(CNV) in our series and in the Levison et al.a report
RE right eye, LE left eye, Beva bevacizumab, Rani Ranibizumab, Afli aflibercept, PDT photodynamic therapy, FU follow-up, BCVA best-corrected visual acuity
a See Ref. [6]
b With eccentric vision
Patient Presentation Eye with CNV CNV treatment N tretments FU (years) Final BCVA
1 Unilateral LE Beva 3 4 RE 20/20 LE 20/60
2 Bilateral LE Beva 3 2 RE 20/25 LE 20/50
3 Bilateral RE Rani + Afli 12 + 5 3 RE 20/40 LE 20/20
4 Unilateral LE PDT 1 11 RE 20/40b LE 20/20
Levison et al.a Bilateral RE Beva 3 0.4 RE 20/20 LE HM
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Fig. 1 Case 1. a, b Color fundus photos at presentation. a The right fundus was found to be normal; b the left fundus revealed a well‑delineated 
area of retinal pigment epithelium atrophy in the inferonasal macula with foveal sparing. c, e Early and late phase fluorescein angiography images of 
the right eye were normal. d, f In the left eye, there was early diffuse hyperfluorescence with a hypofluorescent border. In late phase, there was late 
staining of a patch in the center of the lesion. g, h Humphrey visual field 24‑2 revealed a full visual field in the right eye and a superior paracentral 
scotoma corresponding to the lesion in the left eye
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presentation. BCVA was 20/30 in the RE and 20/20 
in the LE. Dilated fundus examination showed multi-
ple, well-demarcated zonal areas of outer retinal atro-
phy at the posterior pole and at the mid periphery of 
both eyes (Fig. 7). There were pigmented brownish dots 
located mainly at the margins of the atrophic areas 
but also within the lesions bilaterally. FAF in both eyes 
revealed a trizonal pattern and a demarcating hyper-
FAF line between the involved and uninvolved retina 
(Fig. 7); these findings were suggestive of AZOOR [4]. 
After 2 months, a progression of the zonal lesions was 
found in both eyes; in the RE, the progression occurred 
around the disc and towards the fovea and develop-
ment of a subfoveal type 2 CNV  was noted (Fig.  8). 
Over a course of 3  years the patient underwent intra-
vitreal anti-VEGF injections on a treat-and-extend regi-
men (12 ranibizumab and 5 aflibercept injections) and 
her vision has stabilized to 20/40 in the RE. During 
treatment there was zonal progression at the right mac-
ula (Fig. 8). In the LE the zonal lesion at the posterior 
pole remained stable with fovea sparing and patient 
remained asymptomatic with a BCVA of 20/20.
Case 4
In 2004 a 47 year-old white male presented with 2 months 
history of blurred vision in the RE, associated with pho-
topsias. BCVA was 20/50 in the RE and 20/20 in the LE. 
Fundus examination of the RE showed a peripapillary 
lesion. Fundus examination of the LE was unremarkable. 
FAF of the right peripapillary lesion showed a trizonal 
pattern and a hyperautofluorescent border between the 
involved and uninvolved retina [5]. Upon consultation 
of the recent literature at the time [7], the diagnosis of 
AZOOR was made. Small haemorrhages were observed 
at the temporal side of the lesion and fluorescein angiog-
raphy showed the presence of a choroidal neovasculari-
zation. Decision was made to perform a standard PDT 
Fig. 2 Case 1. Fundus autofluorescence (FAF) at presentation (a), day 10 (b), week 3 (c), month 2 (d), and month 5 (e). At presentation (a), there was 
a trizonal FAF pattern. There was an area of diffuse hypoFAF (yellow star) surrounded by a large area of speckled FAF (green asterisk). These areas 
were circumscribed by a continuous hyper‑FAF demarcation line (blue arrow) outside of which the retina appeared normal (red asterisk). In b–d, 
there was FAF evidence of lesion expansion in areas encircled by the green dashed line. Of note, in 3C, there is no demarcation line around the area 
of new expansion, possibly indicating a very recent change. Between month 2 and month 5, there was minimal evidence of lesion change
Fig. 3 Case 1. Spectral‑domain optical coherence tomography 
images of the left eye at presentation (a), day 10 (b), week 3 (c), 
week 6 (d), week 10 (e), and month 5 (f). At presentation (a) there 
was evidence of normal foveal contour with outer retinal changes 
disrupting the continuity of the ellipsoid zone band. At day 10 (b), 
there was mild subretinal fluid nasal to the fovea. At week 3 (c), 
there was a significant increase in the quantity of subretinal fluid. 
There was evidence of hyperreflective material within the subretinal 
fluid that may represent fibrin. Below the subretinal fluid, there 
appeared to be layered hyperreflective bands which could represent 
the layering of the fibrin. By week 6 (d), there was more fluid, and 
a consolidation of the hyperreflective material. By week 10 and 
month 5, there is resolution of the subretinal fluid with persistent 
well‑defined hyperreflective material consistent with retinal scar
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Fig. 4 Case 2. Multimodal retinal imaging at presentation. a, b Fundus examination revealed bilateral peripapillary atrophy with drusen‑like 
material and retinal swelling at the macula of the left eye (LE). c, d Fundus autofluorescence (FAF) showed bilateral zonal peripapillary hypoFAF 
areas surrounded by a granular patchy hyper‑FAF border. In the LE (d), a zonal defect with similar characteristics was detected superior to the fovea. 
e, f Fluorescein angiography (FA) showed bilateral peripapillary hyperfluorescence. f FA of the LE showed dye leakage from a juxtafoveal type 2 
choroidal neovascularizarition
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with a single spot of 2.5  mm focused on the temporal 
part of the zonal lesion. Three months after treatment no 
improvement of visual acuity was recorded. The PDT was 
not repeated and during follow-up the CNV enlarged 
resulting in macular scarring. In 2005 there was a cen-
tral fibrotic pattern with persistent peripheral haemor-
rhages and subretinal fluid. In the RE BCVA improved 
from 20/100 to 20/40, with an eccentric viewing; this 
eye had no longer a reading ability. From 2005 to 2015, a 
progressive enlargement of the scar was noted in the RE 
(Fig. 9). In 2009 small peripapillary lesions were found in 
the LE. FAF features of these lesions were consistent with 
AZOOR [4]. These zonal lesions increased in size during 
follow-up (Fig. 9) and remained stable thereafter. At the 
last follow-up visit in 2015 the left eye eye maintained a 
BCVA of 20/20, without any symptoms.
Discussion
AZOOR is a rare condition that occurs most frequently 
in young females. Presentation may be unilateral or bilat-
eral, with simultaneous or sequential involvement. Prog-
nosis is generally favorable as the central vision is often 
spared. However, photoreceptor and RPE atrophy make 
visual field loss recovery quite infrequent [8, 9].
Although the primary lesion seems to be related to 
photoreceptor outer segment dysfunction [10, 11], its 
underlying etiology is unknown, and its pathogenic 
mechanisms remain uncertain. Inflammatory disease has 
been hypothesized [12], and a history of autoimmune 
inflammatory systemic disease has been noted in at least 
18% of patients [13]. However the benefit of oral steroid 
treatment for this condition has not been well estab-
lished. Moreover, some authors have found evidence of 
disseminated fungal infection [14], and a possible viral 
etiology has been supported by functional improvement 
Fig. 5 Case 2. Fundus autofluorescence (FAF) at presentation (a, b), 1 month after 1 anti‑VEGF injection (c, d) and 1 month after 3 anti‑VEGF 
injections (e, f). c, d After the first injection, bilateral zonal progression was noted. FAF showed the typical trizonal pattern consisting of an hypo‑FAF 
area (yellow stars) surrounded by a large area of speckled FAF (green asterisks), circumscribed by a continuous annular hyper‑FAF demarcation line 
(blue arrows) at the junction between the involved and uninvolved retina (red asterisks). c In the right eye (RE) FAF showed enlargement of the 
peripapillary zonal lesion and new hyperFAF zonal lesions appeared temporal to the fovea. d In the left eye (LE) FAF showed progression of the 
zonal macular lesion with foveal involvement. e, f After the third injection FAF showed bilateral progression of the zonal lesions with confluence of 
the lesions in the RE (e) and foveal sparing. In the LE (f), the hyper‑FAF annular outer border lesion was no longer detectable
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in patients with AZOOR-like illness that were treated 
with oral valacyclovir [15].
The clinical onset of AZOOR is usually marked by pho-
topsias and acute scotomas, with minimal or no fundus 
and angiographic changes. The average age at initial pres-
entation is 36.7 years (with a range age of 13 to 79 years), 
with a predominance in women (76% of cases), and nor-
mal fundus appearance in 76% of cases [13]. Our AZOOR 
cases are therefore atypical with regards to their age at 
onset, as well as their compounded clinical presentation 
and course. However, our cases meet the multimodal 
imaging diagnostic criteria of AZOOR [4] and present 
with typical autofluorescence and clinical features that 
are indisputably part of the AZOOR spectrum. The 
cases presented in this study may be classified as AAOR, 
described by Gass and Stern as a variant of AZOOR and 
characterized by a progressively irregular annular band 
of grey-white deep retinal opacification in a peripapil-
lary location [2, 16]. The most noteworthy aspect of our 
cases is the concomitance of type 2 choroidal neovascu-
larizations. In our series the mean age of patients was 
younger than the mean age reported in the literature on 
AZOOR [13]. It is possible that the mean age deviation 
of our cases from the mean age reported in the current 
literature may have contributed to the development of 
the CNV. Of note our youngest patient (case 3) received 
more anti-VEGF injections than the other cases. Indeed 
she was highly discerning for minimal changes of her 
vision which usually correlated with minimal structural 
changes on OCT.
CNV is an extremely rare complication of AZOOR [4–
6]. To the best of our knowledge only 2 cases of AZOOR 
complicated by CNV have been described in the current 
literature [5, 6]. The first case was reported by Cohen 
and Jampol in 2007 and PDT was used for treating the 
CNV [5]. Six months after treatment, CNV enlargement 
and scarring with no progression of the zonal lesion was 
reported [5]. In the present study we report the long-
term follow-up of the case originally described by Cohen 
and Jampol (case 4). In this case we report a progressive 
enlargement of the central scar in the treated eye and 
subsequent mild involvement of the fellow eye with no 
CNV complication.
Levison et  al. [6] recently reported another case of 
CNV in AZOOR in a 74  year-old female. This patient 
underwent treatment for bilateral AZOOR with systemic 
steroids, methotrexate and intravitreal dexamethasone 
implants. She subsequently developed a CNV in the right 
eye which was successfully treated with three intravitreal 
Fig. 6 Case 2. Spectral‑domain optical coherence tomography (SD‑OCT) scan after 3 anti‑VEGF injections in the left eye. a, b SD‑OCT scan of right 
eye (a) and left eye (b) revealed photoreceptor dysfunction by showing disruption of the ellipsoid zone (white arrows) with thinning of the outer 
nuclear layer (white asterisks). b SD‑OCT scan of the left eye showed presence of well‑defined hyperreflective material consistent with retinal scar
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bevacizumab injections. However long-term follow-up 
was not reported [6].
In the present study we report the multimodal retinal 
imaging and the long-term clinical course of four patients 
presenting with AZOOR complicated by choroidal neo-
vascularization, treated with intravitreal anti-VEGF 
agents (in 3 cases) and with PDT (in one case).
Although VEGF plays an important role in the main-
tenance of both retinal and choroidal circulations and 
is one of the key neurotrophic factors, intravitreal anti-
VEGF injections presently represent the established 
treatment for active CNV. In our patients a remission of 
the choroidal neovascular activity was achieved following 
administration of anti-VEGF agents. However, zonal or 
multizonal  progression was observed  during treatment. 
Given the short period between the anti-angiogenic 
treatment and AZOOR progression, a causal relation-
ship between the treatment and the zonal progression 
could be considered. Indeed, some authors have ques-
tioned the safety of VEGF neutralization, and advised 
cautious administration of intravitreal anti-VEGF. In pre-
clinical studies, after systemic neutralization of VEGF, a 
significant increase in retinal cell apoptosis in the inner 
and outer nuclear layers occurred in mice [17]. Moreover, 
bevacizumab has been reported to neutralize the protec-
tive effect of VEGF on retinal ganglion cells from induced 
oxidative stress [18]. Other authors have raised the issue 
of ultrastructural toxicity, consisting of mitochondrial 
disruption in the inner segments of photoreceptors, after 
intravitreal bevacizumab injections in rabbit eyes [19]. By 
contrast, multifocal electroretinography has shown no 
short-term cone photoreceptor toxicity after intravitreal 
bevacizumab administration [20].
In our cases, it is unclear whether the observed zonal 
progression was accelerated from anti-VEGF treat-
ment, or is attributable to the natural course of the dis-
ease. In case 2, striking progression of the zonal lesions 
was observed in both eyes  during anti-VEGF treatment 
administration in one eye. This finding might be related 
to the minimal systemic diffusion of the intravitreal drug 
and to its possible effect on the fellow eye, as previously 
hypothesized [21, 22].
The presence of CNV expands the clinical spectrum of 
AZOOR. While the progressive nature of AZOOR has 
been well documented [23–26], little is known about the 
clinical course of AZOOR complicated by CNV.
Fig. 7 Case 3. Wide field color image and wide field fundus autofluorescence (FAF) at presentation. a, b Wide field color image showed 
multiple, well‑demarcated zonal areas of outer retinal atrophy that appeared slightly depigmented, with an increased visualization of the major 
underlying choroidal vessels. a In the right eye, there was one main zonal area in the posterior pole and two additional areas in the nasal and the 
supero‑temporal mid‑periphery. b In the left eye three zonal areas were located at the posterior pole and the temporal mid‑periphery. c, d FAF 
showed hypo‑FAF with granular hyper‑FAF signal in correspondence of these depigmented areas. A leading border of hyper‑FAF was evident at the 
junction between the involved and uninvolved retina
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It is possible that in our series the zonal progression 
was merely related to the progressive nature of AZOOR 
in which the CNV was the expression of the underlying 
active disease.
In our experience, intravitreal anti-VEGF treatment 
was effective for the stabilization of the CNV compli-
cating AZOOR. However, a concomitant progression 
of the zonal lesions was observed during treatment. 
Further studies are required to define the pathogenetic 
mechanisms underlying this rare association and the 
role of treatment in the progression of the zonal lesions.
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